Sinha S, Khan A, Qureshi AM, et al. - Researchers undertook a retrospective review to analyze pediatric patients with congenital heart disease who were treated with transcatheter or hybrid aortic valve replacement using a Melody Valve or Sapien S3/XT valve, to ultimately, report their initial experience with pediatric transcatheter aortic valve replacement. This analysis included cases with transcatheter valves implanted on cardiopulmonary bypass. Total participants were 8, including two had Melody valve implantation and 6 received a Sapien valve (one XT/five S3). The participants were observed for an average of 16 months (range 1–208 weeks). No early or late deaths were documented. No embolic events occurred, and good performance was displayed by all valves in the immediate postoperative period. On the basis of the findings, it was concluded that transcatheter valves afford a reasonable option instead of traditional surgical aortic valve replacement in specific pediatric patients who are suboptimal surgical candidates. Hybrid approaches and valve delivery on cardiopulmonary bypass has been employed in smaller patients. In young patients, no inquiry has been made regarding the long-term performance of these valves.